NCT02377336

GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study of GS-6615 in Subjects With Chronic Stable Angina and Coronary Artery Disease

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Gilead Sciences · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the effect of GS-6615 in adults with chronic stable angina and coronary artery disease (CAD) receiving a stable daily dose of up to 2 antianginal medications. The study will consist of two periods: a 1 to 3 week Qualifying Period and a Treatment Period lasting 13 days (± 3 days). During the Qualifying Period and at the end of the Treatment Period, participants will undergo exercise tolerance testing.

Conditions

• Ischemic Heart Disease

Interventions

Type	Name	Description
DRUG	GS-6615	GS-6615 tablets administered orally
DRUG	Placebo	Placebo to match GS-6615 tablets administered orally

Timeline

• Start date: 2015-05-01
• Primary completion: 2016-08-01
• Completion: 2016-08-01
• First posted: 2015-03-03
• Last updated: 2015-06-08